Uroplasty (NASDAQ:UPI) & Its Rivals Head-To-Head Contrast

Uroplasty (NASDAQ: UPI) is one of 19 public companies in the “Medical Devices & Implants” industry, but how does it contrast to its competitors? We will compare Uroplasty to related companies based on the strength of its profitability, institutional ownership, analyst recommendations, earnings, valuation, dividends and risk.

Profitability

This table compares Uroplasty and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Uroplasty -31.58% -87.33% -60.82%
Uroplasty Competitors -101.23% -92.70% -30.32%

Institutional and Insider Ownership

54.8% of shares of all “Medical Devices & Implants” companies are owned by institutional investors. 11.9% of shares of all “Medical Devices & Implants” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent ratings and target prices for Uroplasty and its competitors, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Uroplasty 0 0 0 0 N/A
Uroplasty Competitors 110 728 1026 10 2.50

As a group, “Medical Devices & Implants” companies have a potential upside of 36.76%. Given Uroplasty’s competitors higher possible upside, analysts plainly believe Uroplasty has less favorable growth aspects than its competitors.

Risk & Volatility

Uroplasty has a beta of -1.26, meaning that its share price is 226% less volatile than the S&P 500. Comparatively, Uroplasty’s competitors have a beta of 0.47, meaning that their average share price is 53% less volatile than the S&P 500.

Valuation & Earnings

This table compares Uroplasty and its competitors gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Uroplasty N/A N/A -4.07
Uroplasty Competitors $1.67 billion $207.58 million 80.89

Uroplasty’s competitors have higher revenue and earnings than Uroplasty. Uroplasty is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Summary

Uroplasty competitors beat Uroplasty on 6 of the 8 factors compared.

Uroplasty Company Profile

Cogentix Medical, Inc. (Cogentix Medical) is a medical device company. The Company is engaged in the design, development, manufacturing and marketing of products for endoscopy with its product lines featuring a visualization system and sterile disposable microbial barrier, known as EndoSheath technology, providing users with endoscope turnover. The Company’s products include Urgent PC Neuromodulation System, Macroplastique Bulking Agent, Endoscopy Systems and EndoSheath Technology. The Company is also engaged in the commercialization of the Urgent PC Neuromodulation System, a device which delivers percutaneous tibial nerve stimulation (PTNS) for the office-based treatment of overactive bladder (OAB). Its Macroplastique is an injectable soft-tissue bulking agent used to treat stress urinary incontinence (SUI) due to intrinsic sphincter deficiency (ISD). The Company offers 5000 and 7000 series of endoscopes, which are video endoscopy systems.

Receive News & Ratings for Uroplasty Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uroplasty Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply